A detailed history of Pathstone Holdings, LLC transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Pathstone Holdings, LLC holds 49,378 shares of RXRX stock, worth $281,454. This represents 0.0% of its overall portfolio holdings.

Number of Shares
49,378
Previous 47,961 2.95%
Holding current value
$281,454
Previous $359,000 9.47%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

BUY
$5.92 - $8.6 $8,388 - $12,186
1,417 Added 2.95%
49,378 $325,000
Q2 2024

Aug 14, 2024

BUY
$7.35 - $10.05 $4,968 - $6,793
676 Added 1.43%
47,961 $359,000
Q1 2024

May 13, 2024

BUY
$9.13 - $15.52 $11,485 - $19,524
1,258 Added 2.73%
47,285 $471,000
Q4 2023

Feb 14, 2024

BUY
$5.09 - $10.79 $234,277 - $496,631
46,027 New
46,027 $453,000

Others Institutions Holding RXRX

About RECURSION PHARMACEUTICALS, INC.


  • Ticker RXRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 180,480,000
  • Market Cap $1.03B
  • Description
  • Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...
More about RXRX
Track This Portfolio

Track Pathstone Holdings, LLC Portfolio

Follow Pathstone Holdings, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pathstone Holdings, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pathstone Holdings, LLC with notifications on news.